comparemela.com

Latest Breaking News On - Grifols group - Page 6 : comparemela.com

EQS-News: Biotest AG: Biotest AG opens 12th plasma collection centre in Hungary

EQS-News: Biotest AG / Key word(s): Miscellaneous Biotest AG: Biotest AG opens 12th plasma collection centre in Hungary 25.04..

Comunidad autonoma de catalunaBiotest hungaria kftMonika buttkereitDirk neumGrifols groupPlasma service europe gmbEurope theChief operating officer plazmaszolgManaging directorPlasma service europeBiotest hungariaPrime standard

EQS-News: Biotest AG: Biotest AG opens 10th plasma collection centre in Germany

EQS-News: Biotest AG / Key word(s): Miscellaneous Biotest AG: Biotest AG opens 10th plasma collection centre in Germany 20.04..

Comunidad autonoma de catalunaDirk neumSebastian witteMonika buttkereitHenrik oehmeMarina hohenbPlasma service europe gmbGrifols groupService europe gmbhCentre director sebastianManaging directorPlasma service europePlasma service europe gmbhPrime standard

Biotest AG: Biotest achieves important milestone in phase III trial in acquired fibrinogen deficiency

EQS-News: Biotest AG / Key word: Study Biotest AG: Biotest achieves important milestone in phase III trial in acquired fibrinogen deficiency 30.03.2023 / 08:48 CET/CEST The. | March 30, 2023

Comunidad autonoma de catalunaUnited statesMonika buttkereitDirk neumGrifols groupClinical strategy development at biotestAdjusted fibrinogen replacement strategyData safety monitoring boardDirector clinical strategyPrime standardBiotest ag stock exchangePress releaseEficiency bio3 de0005227235

EQS-News: Biotest AG: Biotest achieves important milestone in phase III trial in acquired fibrinogen deficiency

EQS-News: Biotest AG / Key word(s): Study Biotest AG: Biotest achieves important milestone in phase III trial in acquired fibrinogen .

Comunidad autonoma de catalunaUnited statesDirk neumMonika buttkereitGrifols groupClinical strategy development at biotestAdjusted fibrinogen replacement strategyData safety monitoring boardDirector clinical strategyPrime standard

Biotest AG: Biotest achieves important milestone in phase III trial in acquired fibrinogen deficienc

EQS-News: Biotest AG / Key word(s): StudyBiotest AG: Biotest achieves important milestone in phase III trial in acquired fibrinogen deficiency 30.03.2023 / 08:48 CET/CESTThe issuer is solely responsible for the content of this announcement. PRESS RELEASE   Biotest achieves important milestone in phase III.

Comunidad autonoma de catalunaUnited statesMonika buttkereitDirk neumGrifols groupDistribution servicesClinical strategy development at biotestAdjusted fibrinogen replacement strategyData safety monitoring boardDirector clinical strategyPrime standardCorporate newsRegulatory announcements

vimarsana © 2020. All Rights Reserved.